← Leaderboards
Amynah Amir Ali Pradhan
University Of California Los Angeles
$7,730,866
Attributed
$8,842,218
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,842,218 · 8
By mechanism
R01$3,244,404 · 2
UG3$2,316,866 · 1
R61$1,780,871 · 2
R00$743,264 · 1
R21$439,725 · 1
K99$317,088 · 1
Top collaborators
- Andrew C Charles1 shared
- Vsevolod Katritch1 shared
- Susruta Majumdar1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Kevin Christopher Brennan$11,140,769
- Sinifunanya Elvee Nwaobi$574,830
- Julian P Whitelegge$13,061,525
- Kirsten Tillisch$1,968,173
- Bruce D Naliboff$4,455,401
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicPainAffectAcuteComplexOpioidSignal TransductionAgonistReceptorElectrophysiology (Science)EmotionalKnock-OutOpioid ReceptorAbsence Of Pain SensationNeuronsMigrainePharmaceutical PreparationsAnimalsAdverse EffectsMediatingPropertyAnimal ModelInsightAuras
Grant awards (20)
The role of delta opioid receptors in trigeminovascular pain$465,677
R01 · FY2025 · NS · contact PI
Development of PAC1 receptor antagonists for the treatment of Headache Disorders$1,325,500
R61 · FY2024 · NS · contact PI
The role of delta opioid receptors in trigeminovascular pain$456,209
R01 · FY2024 · NS · contact PI
A novel platform for the discovery and characterization of migraine therapies$455,371
R61 · FY2024 · NS
The role of delta opioid receptors in trigeminovascular pain$475,717
R01 · FY2023 · NS · contact PI
The development of delta opioid receptor agonists for the treatment of opioid withdrawal associated behaviors$2,316,866
UG3 · FY2022 · DA · contact PI
The role of delta opioid receptors in trigeminovascular pain$354,350
R01 · FY2020 · DA · contact PI
The role of delta opioid receptors in trigeminovascular pain$365,444
R01 · FY2019 · DA · contact PI
Role of HDAC6 in cephalic pain$199,875
R21 · FY2019 · NS · contact PI
The role of delta opioid receptors in trigeminovascular pain$353,477
R01 · FY2018 · DA · contact PI
Role of HDAC6 in cephalic pain$239,850
R21 · FY2018 · NS · contact PI
The role of delta opioid receptors in trigeminovascular pain$43,931
R01 · FY2018 · DA · contact PI
The role of delta opioid receptors in trigeminovascular pain$353,570
R01 · FY2017 · DA · contact PI
Diversity supplement for the role of delta opioid receptors in trigeminovascular pain$43,931
R01 · FY2017 · DA · contact PI
The role of delta opioid receptors in trigeminovascular pain$332,098
R01 · FY2016 · DA · contact PI
In Vivo Implications of Agonist Selective Activation of Delta Opioid Receptor$245,264
R00 · FY2015 · DA · contact PI
In Vivo Implications of Agonist Selective Activation of Delta Opioid Receptor$249,000
R00 · FY2014 · DA · contact PI
In Vivo Implications of Agonist Selective Activation of Delta Opioid Receptor$249,000
R00 · FY2013 · DA · contact PI
In Vivo Implications of Agonist Selective Activation of Delta Opioid Receptor$158,544
K99 · FY2012 · DA · contact PI
In Vivo Implications of Agonist Selective Activation of Delta Opioid Receptor$158,544
K99 · FY2011 · DA · contact PI